ifosfamide has been researched along with Lymphoma, Large B-Cell, Diffuse in 86 studies
Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate." | 9.11 | ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004) |
| "One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i." | 9.09 | High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001) |
| " Two toxic deaths were observed." | 6.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| " Dosing was modified for elderly patients." | 5.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate." | 5.11 | ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004) |
| "One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i." | 5.09 | High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001) |
| " This is a report of a 64-year-old female with relapsed double-hit diffuse large B-cell lymphoma who developed severe altered mental status and neurological symptoms after receiving a second dose of ifosfamide as part of her salvage standard dose R-IE (rituximab, ifosfamide, etoposide), in preparation for chimeric antigen receptor T-cell therapy." | 3.91 | Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy. ( Gharaibeh, EZ; Powers, BC; Salacz, ME; Telfah, M, 2019) |
| "We present a 56-year-old woman who received chemotherapy for relapsed diffuse large B-cell lymphoma and developed posterior reversible encephalopathy syndrome (PRES) with generalized seizures 27 days after treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE)." | 3.81 | [Malignant lymphoma complicated with posterior reversible encephalopathy]. ( Hansen, PB; Thomsen, RH; Zakarian, K, 2015) |
| "To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial." | 3.77 | The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. ( Boudova, L; Briere, J; Bron, D; Chevalier, C; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Jack, A; Mounier, N; Rosenwald, A; Schmitz, N; Soulier, J; Sundstrom, C; Thieblemont, C; Trougouboff, P; Voelker, HU; Ysebaert, L, 2011) |
| " We conducted an investigator initiated, single-center, open-label, prospective phase 1 study evaluating the safety and efficacy of CFZ in combination with rituximab, ifosfamide, carboplatin, and etoposide (C-R-ICE) in high-dose chemotherapy with autologous stem cell transplant (HDC-ASCT) eligible patients with R/R DLBCL (NCT01959698)." | 3.30 | Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. ( Anampa-Guzmán, A; Block, A; Darrall, A; DeMarco, J; Ghione, P; Groman, A; Hernandez-Ilizaliturri, FJ; Hutson, A; Johnson, M; Kader, A; Kostrewa, J; Lund, I; Mavis, C; McWhite, K; Mohr, A; Nichols, J; Przespolewski, E; Sait, SJ; Sundaram, S; Thomas, R; Torka, P; Wong, J, 2023) |
| " Carfilzomib, an irreversible proteasome inhibitor, can overcome acquired rituximab-chemotherapy resistance and, when combined with R-ICE, improves outcomes in patients with R/R DLBCL." | 3.30 | Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P, 2023) |
| " Our results suggest that f-R-ICE is a safe and effective salvage therapy for r/r DLBCL and can be used for older patients and/or those with high CCI scores in outpatient clinics." | 2.94 | Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. ( Imai, Y; Shiseki, M; Tanaka, J; Tanaka, N; Yoshinaga, K, 2020) |
| " We conducted a single-center phase 1 study evaluating dose-escalated ibrutinib, in a 3-by-3 design, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in physiologically transplant-eligible rel/ref DLBCL patients." | 2.87 | A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. ( Courtien, AI; Devlin, SM; Drullinsky, P; Gerecitano, J; Kumar, A; Matasar, MJ; McCall, SJ; Miller, ST; Moskowitz, CH; Noy, A; Palomba, ML; Portlock, CS; Sauter, CS; Schoder, H; Straus, DJ; Younes, A; Zelenetz, AD, 2018) |
| " Two toxic deaths were observed." | 2.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| "To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL)." | 2.74 | [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. ( Cen, XN; Chen, H; Han, MZ; Han, XH; He, XH; Huang, H; Huang, HQ; Jiang, WQ; Liu, P; Ma, J; Ren, HY; Shen, XM; Shi, YK; Wang, C; Wang, JM; Yang, S; Zhou, SY; Zhu, J, 2009) |
| "Febrile neutropenia was the most frequent grade 3 or 4 nonhematologic toxicity; it occurred in 7." | 2.71 | Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. ( Filippa, DA; Gencarelli, A; Kewalramani, T; Moskowitz, CH; Nimer, SD; Noy, A; O'Connor, O; Portlock, C; Qin, J; Straus, D; Teruya-Feldstein, J; Waxman, A; Yahalom, J; Zelenetz, AD, 2004) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | 2.68 | Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| "A gastrosplenic fistula is a rare complication of gastric and splenic lymphomas which can occur spontaneously or secondary to chemotherapy." | 2.46 | Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma. ( D'Souza, R; Khan, F; McKimm, E; Vessal, S, 2010) |
| " The purpose of this study was to explore the efficacy and safety of programmed cell death 1 (PD-1) blockade combined with ICE regimen (P-ICE) in the treatment of R/R DLBCL patients." | 1.91 | PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma. ( Bai, B; Gao, Y; He, Y; Huang, C; Huang, H; Ping, L; Shi, L; Wang, X, 2023) |
| " Dosing was modified for elderly patients." | 1.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "Ifosfamide is an alkylating agent used to treat different types of malignancies including lymphomas, sarcomas and germinal cell tumors." | 1.39 | Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report. ( Bhardwaj, H; Cherry, MA; Hopps, S; Pant, S; Srour, S, 2013) |
| "Fifty-six patients with malignant lymphoma of aggressive histologic type (51 large cell, three diffuse undifferentiated, and two nodular mixed) were treated with three non-cross-resistant combination chemotherapy regimens that were introduced sequentially according to the response to therapy." | 1.27 | Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. ( Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.16) | 18.7374 |
| 1990's | 12 (13.95) | 18.2507 |
| 2000's | 29 (33.72) | 29.6817 |
| 2010's | 35 (40.70) | 24.3611 |
| 2020's | 9 (10.47) | 2.80 |
| Authors | Studies |
|---|---|
| Paszkiewicz-Kozik, E | 1 |
| Michalski, W | 1 |
| Taszner, M | 1 |
| Mordak-Domagała, M | 1 |
| Romejko-Jarosińska, J | 1 |
| Knopińska-Posłuszny, W | 1 |
| Najda, J | 1 |
| Borawska, A | 1 |
| Chełstowska, M | 1 |
| Świerkowska, M | 1 |
| Dąbrowska-Iwanicka, A | 1 |
| Malenda, A | 1 |
| Druzd-Sitek, A | 1 |
| Konecki, R | 1 |
| Kumiega, B | 1 |
| Osowiecki, M | 1 |
| Ostrowska, B | 1 |
| Szpila, T | 1 |
| Szymański, M | 1 |
| Targoński, Ł | 1 |
| Domańska-Czyż, K | 1 |
| Popławska, L | 1 |
| Giebel, S | 1 |
| Lange, A | 1 |
| Pluta, A | 1 |
| Zaucha, JM | 1 |
| Rymkiewicz, G | 1 |
| Walewski, J | 1 |
| Pavlovsky, M | 1 |
| Cubero, D | 1 |
| Agreda-Vásquez, GP | 1 |
| Enrico, A | 1 |
| Mela-Osorio, MJ | 1 |
| San Sebastián, JA | 1 |
| Fogliatto, L | 1 |
| Ovilla, R | 1 |
| Avendano, O | 1 |
| Machnicki, G | 1 |
| Barreyro, P | 1 |
| Trufelli, D | 1 |
| Villanova, P | 1 |
| Torka, P | 2 |
| Groman, A | 1 |
| Wong, J | 1 |
| Nichols, J | 1 |
| Kader, A | 1 |
| Mavis, C | 1 |
| Anampa-Guzmán, A | 1 |
| Sait, SJ | 1 |
| Block, A | 1 |
| Przespolewski, E | 1 |
| Mohr, A | 1 |
| Lund, I | 1 |
| McWhite, K | 1 |
| Kostrewa, J | 1 |
| DeMarco, J | 1 |
| Johnson, M | 1 |
| Darrall, A | 1 |
| Thomas, R | 1 |
| Sundaram, S | 1 |
| Ghione, P | 1 |
| Hutson, A | 1 |
| Hernandez-Ilizaliturri, FJ | 2 |
| Burke, GAA | 1 |
| Vinti, L | 1 |
| Kabickova, E | 1 |
| Beishuizen, A | 1 |
| Tacyildiz, N | 1 |
| Uyttebroeck, A | 1 |
| Kang, HJ | 1 |
| Luisi, F | 1 |
| Minard-Colin, V | 2 |
| Burkhardt, B | 1 |
| Tamegnon, M | 1 |
| Sun, S | 1 |
| Curtis, M | 1 |
| Deshpande, S | 1 |
| Nottage, K | 1 |
| Howes, A | 1 |
| Srinivasan, S | 1 |
| Bhojwani, D | 1 |
| Norris, R | 1 |
| Cairo, M | 1 |
| Ping, L | 1 |
| Gao, Y | 1 |
| He, Y | 1 |
| Bai, B | 1 |
| Huang, C | 1 |
| Shi, L | 1 |
| Wang, X | 1 |
| Huang, H | 2 |
| Lin, LH | 1 |
| Ghasemi, M | 1 |
| Burke, SM | 1 |
| Mavis, CK | 1 |
| Nichols, JR | 1 |
| Mager, DE | 1 |
| Goey, AKL | 1 |
| McMillan, AK | 1 |
| Phillips, EH | 1 |
| Kirkwood, AA | 1 |
| Barrans, S | 1 |
| Burton, C | 1 |
| Rule, S | 1 |
| Patmore, R | 1 |
| Pettengell, R | 1 |
| Ardeshna, KM | 1 |
| Lawrie, A | 1 |
| Montoto, S | 1 |
| Paneesha, S | 1 |
| Clifton-Hadley, L | 1 |
| Linch, DC | 2 |
| Sang, W | 1 |
| Shi, M | 1 |
| Yang, J | 1 |
| Cao, J | 1 |
| Xu, L | 1 |
| Yan, D | 1 |
| Yao, M | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Zhang, B | 1 |
| Sun, K | 1 |
| Song, X | 1 |
| Sun, C | 1 |
| Jiao, J | 1 |
| Qin, Y | 1 |
| Sang, T | 1 |
| Ma, Y | 1 |
| Wu, M | 1 |
| Gao, X | 2 |
| Cheng, H | 1 |
| Yan, Z | 1 |
| Li, D | 1 |
| Sun, H | 1 |
| Zhu, F | 1 |
| Wang, Y | 1 |
| Zeng, L | 1 |
| Li, Z | 1 |
| Zheng, J | 1 |
| Xu, K | 1 |
| Tanaka, N | 1 |
| Imai, Y | 1 |
| Yoshinaga, K | 1 |
| Shiseki, M | 1 |
| Tanaka, J | 1 |
| Gorospe, L | 1 |
| Gallego-Rivera, JI | 1 |
| Rioja-Martín, ME | 1 |
| Chinea-Rodríguez, A | 1 |
| Sauter, CS | 1 |
| Matasar, MJ | 1 |
| Schoder, H | 1 |
| Devlin, SM | 1 |
| Drullinsky, P | 1 |
| Gerecitano, J | 1 |
| Kumar, A | 1 |
| Noy, A | 3 |
| Palomba, ML | 1 |
| Portlock, CS | 2 |
| Straus, DJ | 2 |
| Zelenetz, AD | 4 |
| McCall, SJ | 1 |
| Miller, ST | 1 |
| Courtien, AI | 1 |
| Younes, A | 1 |
| Moskowitz, CH | 4 |
| Gharaibeh, EZ | 1 |
| Telfah, M | 1 |
| Powers, BC | 1 |
| Salacz, ME | 1 |
| Bonnet, E | 1 |
| Tartas, S | 1 |
| Lazareth, A | 1 |
| Jaouen, A | 1 |
| Tamarelle, B | 1 |
| You, B | 1 |
| Maillet, D | 1 |
| Kawaji, Y | 1 |
| Nagata, H | 1 |
| Muramatsu, A | 1 |
| Kuriyama, K | 1 |
| Ohshiro, M | 1 |
| Hirakawa, Y | 1 |
| Iwai, T | 1 |
| Kobayashi, T | 2 |
| Uchiyama, H | 1 |
| Urata, Y | 1 |
| Kuroda, J | 1 |
| Rigaud, C | 1 |
| Auperin, A | 1 |
| Jourdain, A | 1 |
| Haouy, S | 1 |
| Couec, ML | 1 |
| Aladjidi, N | 1 |
| Gandemer, V | 1 |
| Lambliotte, A | 1 |
| Plat, G | 1 |
| Landman-Parker, J | 1 |
| Michon, J | 1 |
| Leblanc, T | 1 |
| Patte, C | 1 |
| Gyan, E | 1 |
| Damotte, D | 1 |
| Courby, S | 1 |
| Sénécal, D | 1 |
| Quittet, P | 1 |
| Schmidt-Tanguy, A | 1 |
| Banos, A | 1 |
| Le Gouill, S | 1 |
| Lamy, T | 1 |
| Fontan, J | 1 |
| Maisonneuve, H | 1 |
| Alexis, M | 1 |
| Dreyfus, F | 1 |
| Tournilhac, O | 1 |
| Laribi, K | 1 |
| Solal-Céligny, P | 1 |
| Arakelyan, N | 1 |
| Cartron, G | 1 |
| Gressin, R | 1 |
| Choi, MK | 1 |
| Kang, ES | 1 |
| Kim, DW | 1 |
| Ko, YH | 1 |
| Seok, H | 1 |
| Park, JH | 1 |
| Pyo, DH | 1 |
| Hoon Lim, D | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Opydo-Chanek, M | 1 |
| Mazur, L | 1 |
| Stojak, M | 1 |
| Feldman, T | 1 |
| Mato, AR | 1 |
| Chow, KF | 1 |
| Protomastro, EA | 1 |
| Yannotti, KM | 1 |
| Bhattacharyya, P | 1 |
| Yang, X | 1 |
| Donato, ML | 1 |
| Rowley, SD | 1 |
| Carini, C | 1 |
| Valentinetti, M | 1 |
| Smith, J | 1 |
| Gadaleta, G | 1 |
| Bejot, C | 1 |
| Stives, S | 1 |
| Timberg, M | 1 |
| Kdiry, S | 1 |
| Pecora, AL | 1 |
| Beaven, AW | 1 |
| Goy, A | 1 |
| Zanelli, M | 1 |
| Valli, R | 1 |
| Capodanno, I | 1 |
| Ragazzi, M | 1 |
| Ascani, S | 1 |
| Pardal, E | 1 |
| Coronado, M | 1 |
| Martín, A | 1 |
| Grande, C | 2 |
| Marín-Niebla, A | 1 |
| Panizo, C | 1 |
| Bello, JL | 1 |
| Conde, E | 2 |
| Hernández, MT | 2 |
| Arranz, R | 2 |
| Bargay, J | 1 |
| González-Barca, E | 1 |
| Pérez-Ceballos, E | 1 |
| Montes-Moreno, S | 1 |
| Caballero, MD | 1 |
| Cheah, CY | 1 |
| Herbert, KE | 1 |
| O'Rourke, K | 1 |
| Kennedy, GA | 1 |
| George, A | 1 |
| Fedele, PL | 1 |
| Gilbertson, M | 1 |
| Tan, SY | 1 |
| Ritchie, DS | 1 |
| Opat, SS | 1 |
| Prince, HM | 1 |
| Dickinson, M | 1 |
| Burbury, K | 1 |
| Wolf, M | 1 |
| Januszewicz, EH | 1 |
| Tam, CS | 1 |
| Westerman, DA | 1 |
| Carney, DA | 1 |
| Harrison, SJ | 1 |
| Seymour, JF | 4 |
| Maruyama, D | 2 |
| Fayad, L | 1 |
| Ansell, SM | 2 |
| Advani, R | 1 |
| Coiffier, B | 2 |
| Stuart, R | 1 |
| Bartlett, NL | 1 |
| Forero-Torres, A | 1 |
| Kuliczkowski, K | 1 |
| Belada, D | 1 |
| Ng, E | 1 |
| Drachman, JG | 1 |
| Swinnen, LJ | 1 |
| Li, H | 1 |
| Quon, A | 1 |
| Gascoyne, R | 1 |
| Hong, F | 1 |
| Ranheim, EA | 1 |
| Habermann, TM | 2 |
| Kahl, BS | 1 |
| Horning, SJ | 1 |
| Advani, RH | 1 |
| Thomsen, RH | 1 |
| Zakarian, K | 1 |
| Hansen, PB | 1 |
| Sun, X | 1 |
| Xu, B | 1 |
| Li, Y | 1 |
| Du, J | 1 |
| Dong, L | 1 |
| Li, G | 1 |
| Wei, X | 1 |
| Song, Y | 1 |
| Landsburg, DJ | 1 |
| Petrich, AM | 1 |
| Abramson, JS | 1 |
| Sohani, AR | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Chavez, JC | 1 |
| Song, K | 1 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Fenske, TS | 1 |
| Jaso, J | 1 |
| Medeiros, LJ | 1 |
| Yang, DT | 1 |
| Nabhan, C | 1 |
| Sarid, N | 1 |
| Joffe, E | 1 |
| Gibstein, L | 1 |
| Avivi, I | 1 |
| Polliack, A | 1 |
| Perry, C | 1 |
| Herishanu, Y | 1 |
| Amorim, S | 1 |
| Fleury, I | 1 |
| Mounier, N | 5 |
| Harel, S | 1 |
| Brice, P | 1 |
| Thieblemont, C | 3 |
| Liu, YF | 1 |
| Hertzberg, M | 1 |
| Gandhi, MK | 1 |
| Trotman, J | 1 |
| Butcher, B | 1 |
| Taper, J | 2 |
| Johnston, A | 1 |
| Gill, D | 1 |
| Ho, SJ | 1 |
| Cull, G | 1 |
| Fay, K | 1 |
| Chong, G | 1 |
| Grigg, A | 1 |
| Lewis, ID | 1 |
| Milliken, S | 1 |
| Renwick, W | 1 |
| Hahn, U | 1 |
| Filshie, R | 1 |
| Kannourakis, G | 1 |
| Watson, AM | 1 |
| Warburton, P | 1 |
| Wirth, A | 1 |
| Hofman, MS | 1 |
| Hicks, RJ | 1 |
| Derenzini, E | 1 |
| Musuraca, G | 1 |
| Fanti, S | 1 |
| Stefoni, V | 1 |
| Tani, M | 1 |
| Alinari, L | 1 |
| Venturini, F | 1 |
| Gandolfi, L | 1 |
| Baccarani, M | 1 |
| Zinzani, PL | 1 |
| Sieniawski, M | 1 |
| Bhartia, S | 1 |
| Wilkinson, J | 1 |
| Proctor, SJ | 2 |
| Conrad, AL | 1 |
| Go, RS | 1 |
| Kinoshita, T | 1 |
| Shi, YK | 1 |
| Yang, S | 1 |
| Han, XH | 1 |
| Ma, J | 1 |
| Ren, HY | 1 |
| Cen, XN | 1 |
| Zhou, SY | 1 |
| Wang, C | 1 |
| Jiang, WQ | 1 |
| Huang, HQ | 1 |
| Wang, JM | 1 |
| Zhu, J | 1 |
| Chen, H | 1 |
| Han, MZ | 1 |
| Shen, XM | 1 |
| Liu, P | 1 |
| He, XH | 1 |
| Gisselbrecht, C | 5 |
| Glass, B | 1 |
| Singh Gill, D | 1 |
| Trneny, M | 1 |
| Bosly, A | 2 |
| Ketterer, N | 1 |
| Shpilberg, O | 1 |
| Hagberg, H | 2 |
| Ma, D | 1 |
| Brière, J | 4 |
| Schmitz, N | 2 |
| Morel, P | 1 |
| Munck, JN | 1 |
| Ranta, D | 1 |
| Tilly, H | 1 |
| Quesnel, B | 1 |
| Thyss, A | 1 |
| Molina, T | 1 |
| Reyes, F | 1 |
| Imtiaz, S | 1 |
| Muzaffar, N | 1 |
| Miwa, A | 1 |
| Sekiguchi, N | 1 |
| Tanimura, A | 1 |
| Homma, C | 1 |
| Shikai, T | 1 |
| Takezako, Y | 1 |
| Yamagata, N | 1 |
| Takezako, N | 1 |
| Patrij, K | 1 |
| Reiser, M | 1 |
| Wätzel, L | 1 |
| Pels, H | 1 |
| Kowoll, A | 1 |
| Herrlinger, U | 1 |
| Engert, A | 1 |
| Linnebank, M | 1 |
| Schackert, G | 1 |
| Vogt-Schaden, M | 1 |
| Egerer, G | 1 |
| Lamprecht, M | 1 |
| Batchelor, TT | 1 |
| Schlegel, U | 1 |
| Schmidt-Wolf, IG | 1 |
| Voelker, HU | 2 |
| Cuccuini, W | 2 |
| Hirchaud, E | 2 |
| Rosenwald, A | 2 |
| Jack, A | 1 |
| Sundstrom, C | 2 |
| Cogliatti, S | 2 |
| Trougouboff, P | 1 |
| Boudova, L | 1 |
| Ysebaert, L | 2 |
| Soulier, J | 2 |
| Chevalier, C | 1 |
| Bron, D | 2 |
| Gaulard, P | 2 |
| Houlgatte, R | 2 |
| Elstrom, RL | 1 |
| Andemariam, B | 1 |
| Martin, P | 1 |
| Ruan, J | 1 |
| Shore, TB | 1 |
| Coleman, M | 1 |
| Leonard, JP | 1 |
| Furman, RR | 1 |
| Khan, F | 1 |
| Vessal, S | 1 |
| McKimm, E | 1 |
| D'Souza, R | 1 |
| Cherry, MA | 1 |
| Bhardwaj, H | 1 |
| Hopps, S | 1 |
| Srour, S | 1 |
| Pant, S | 1 |
| Mappa, S | 1 |
| Marturano, E | 1 |
| Licata, G | 1 |
| Frezzato, M | 1 |
| Frungillo, N | 1 |
| Ilariucci, F | 1 |
| Stelitano, C | 1 |
| Ferrari, A | 1 |
| Sorarù, M | 1 |
| Vianello, F | 1 |
| Baldini, L | 1 |
| Proserpio, I | 1 |
| Foppoli, M | 1 |
| Assanelli, A | 1 |
| Reni, M | 1 |
| Caligaris-Cappio, F | 1 |
| Ferreri, AJ | 1 |
| Hamlin, PA | 1 |
| Kewalramani, T | 2 |
| Qin, J | 2 |
| Satagopan, JM | 1 |
| Verbel, D | 1 |
| Yahalom, J | 2 |
| Nimer, SD | 2 |
| Kawakami, K | 1 |
| Watanabe, Y | 1 |
| Kadowaki, S | 1 |
| Portlock, C | 1 |
| Straus, D | 1 |
| O'Connor, O | 1 |
| Filippa, DA | 1 |
| Teruya-Feldstein, J | 1 |
| Gencarelli, A | 1 |
| Waxman, A | 1 |
| Ueda, C | 1 |
| Nishikori, M | 1 |
| Kitawaki, T | 1 |
| Uchiyama, T | 1 |
| Ohno, H | 1 |
| Jerkeman, M | 1 |
| Leppä, S | 1 |
| Kvaløy, S | 1 |
| Holte, H | 1 |
| Pocali, B | 1 |
| De Simone, M | 1 |
| Annunziata, M | 1 |
| Palmieri, S | 1 |
| D'Amico, MR | 1 |
| Copia, C | 1 |
| Viola, A | 1 |
| Mele, G | 1 |
| Schiavone, EM | 1 |
| Ferrara, F | 1 |
| Humphreys, BD | 1 |
| Forman, JP | 1 |
| Zandi-Nejad, K | 1 |
| Bazari, H | 1 |
| Seifter, J | 1 |
| Magee, CC | 1 |
| Nath, SV | 1 |
| Larson, ML | 1 |
| Enschede, SH | 1 |
| Gregory, SA | 1 |
| Jahnke, K | 1 |
| Wagner, T | 1 |
| Bechrakis, NE | 1 |
| Willerding, G | 1 |
| Coupland, SE | 1 |
| Fischer, L | 1 |
| Thiel, E | 2 |
| Korfel, A | 1 |
| Yokoyama, M | 1 |
| Kubo, Y | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Corazzelli, G | 1 |
| Russo, F | 1 |
| Capobianco, G | 1 |
| Marcacci, G | 1 |
| Della Cioppa, P | 1 |
| Pinto, A | 1 |
| Hertzberg, MS | 1 |
| Crombie, C | 1 |
| Benson, W | 1 |
| Gottlieb, D | 1 |
| Bradstock, KF | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Sugimoto, T | 1 |
| Matano, S | 1 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Moleti, ML | 1 |
| Testi, AM | 1 |
| Giona, F | 1 |
| Malandruccolo, L | 1 |
| Pescarmona, E | 1 |
| Martino, P | 1 |
| Paoloni, F | 1 |
| Barberi, W | 1 |
| Palumbo, G | 1 |
| Mandelli, F | 1 |
| Foa, R | 1 |
| Koizumi, K | 1 |
| Minauchi, K | 1 |
| Odani, T | 1 |
| Kondo, M | 1 |
| Takada, A | 1 |
| Mukai, M | 1 |
| Simpson, L | 1 |
| Colgan, JP | 1 |
| Inwards, DJ | 1 |
| Ristow, KM | 1 |
| Johnston, PB | 1 |
| Markovic, SN | 1 |
| Micallef, IN | 1 |
| Porrata, LF | 1 |
| Witzig, TE | 1 |
| Mateos, MV | 1 |
| Gandarillas, M | 1 |
| Albo, C | 1 |
| Lahuerta, JJ | 1 |
| Fernández-Rañada, JM | 1 |
| Alonso, N | 1 |
| García Vela, JA | 1 |
| Garzón, S | 1 |
| Rodríguez, J | 1 |
| Caballero, D | 1 |
| Jambusaria, A | 1 |
| Shafer, D | 1 |
| Wu, H | 1 |
| Al-Saleem, T | 1 |
| Perlis, C | 1 |
| Cabanillas, F | 2 |
| Burgess, MA | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| Okamoto, M | 1 |
| Maruyama, F | 1 |
| Tsuzuki, M | 1 |
| Nomura, T | 1 |
| Miyazaki, H | 1 |
| Wakita, M | 1 |
| Kojima, H | 1 |
| Sobue, R | 1 |
| Matsui, T | 1 |
| Ino, T | 1 |
| Cortes, JE | 1 |
| Talpaz, M | 1 |
| Kurzrock, R | 1 |
| Reiter, A | 1 |
| Schrappe, M | 1 |
| Parwaresch, R | 1 |
| Henze, G | 1 |
| Müller-Weihrich, S | 1 |
| Sauter, S | 1 |
| Sykora, KW | 1 |
| Ludwig, WD | 1 |
| Gadner, H | 1 |
| Riehm, H | 1 |
| Weintraub, M | 1 |
| Adde, MA | 1 |
| Venzon, DJ | 1 |
| Shad, AT | 1 |
| Horak, ID | 1 |
| Neely, JE | 1 |
| Seibel, NL | 1 |
| Gootenberg, J | 1 |
| Arndt, C | 1 |
| Nieder, ML | 1 |
| Magrath, IT | 1 |
| Soslow, RA | 1 |
| Davis, RE | 1 |
| Warnke, RA | 1 |
| Cleary, ML | 1 |
| Kamel, OW | 1 |
| Engelhard, M | 1 |
| Brittinger, G | 1 |
| Huhn, D | 1 |
| Gerhartz, HH | 1 |
| Meusers, P | 1 |
| Siegert, W | 1 |
| Wilmanns, W | 1 |
| Aydemir, U | 1 |
| Bierwolf, S | 1 |
| Griesser, H | 1 |
| Tiemann, M | 1 |
| Lennert, K | 1 |
| Fridrik, MA | 1 |
| Greil, R | 1 |
| Hausmaninger, H | 1 |
| Krieger, O | 1 |
| Oppitz, P | 1 |
| Stöger, M | 1 |
| Klocker, J | 1 |
| Neubauer, M | 1 |
| Helm, W | 1 |
| Pont, J | 1 |
| Fazeny, B | 1 |
| Hudec, M | 1 |
| Simonitsch, I | 1 |
| Radaszkiewicz, T | 1 |
| Tsujita, Y | 1 |
| Iwao, N | 1 |
| Makino, S | 1 |
| Ohsawa, N | 1 |
| López-Guillermo, A | 1 |
| García-Conde, J | 1 |
| Alvarez-Carmona, AM | 1 |
| León, P | 1 |
| Maldonado, J | 1 |
| Alcalá, A | 1 |
| Zubizarreta, A | 1 |
| Sancho-Tello, R | 1 |
| Carbonell, F | 1 |
| Contreras, E | 1 |
| Besses, C | 1 |
| Hernando, A | 1 |
| Fontanillas, M | 1 |
| Montserrat, E | 1 |
| Jhanwar-Uniyal, M | 1 |
| Gulati, SC | 1 |
| Orlandi, E | 1 |
| Lazzarino, M | 1 |
| Bernasconi, P | 1 |
| Astori, C | 1 |
| Bernasconi, C | 1 |
| Ruiz Hernández, G | 1 |
| Pallardó-Calatayud, J | 1 |
| Ferrer Albiach, C | 1 |
| Balaguer-Martínez, JV | 1 |
| Romero-de-Avila, C | 1 |
| Castillo-Pallarés, FJ | 1 |
| Taylor, PR | 1 |
| Angus, B | 1 |
| Wood, K | 1 |
| Lennard, AL | 1 |
| Lucraft, H | 1 |
| Carey, PJ | 1 |
| Stark, A | 1 |
| Iqbal, A | 1 |
| Haynes, A | 1 |
| Russel, N | 1 |
| Leonard, RC | 1 |
| Culligan, D | 1 |
| Conn, J | 1 |
| Jackson, GH | 1 |
| Bertè, R | 1 |
| Vallisa, D | 1 |
| Civardi, G | 1 |
| Moroni, CF | 1 |
| Lazzaro, A | 1 |
| Cavanna, L | 1 |
| Anderson, NR | 1 |
| Tandon, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk)[NCT00974792] | Phase 2 | 150 participants (Anticipated) | Interventional | 2006-01-31 | Recruiting | ||
| Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| A Phase I Study Combining Ibrutinib With Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients With Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)[NCT02219737] | Phase 1 | 26 participants (Actual) | Interventional | 2014-09-12 | Completed | ||
| Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone (R2-GOD) in Treatment of Relapse/Refractory DLBCL:A Phase I Study[NCT03795571] | Phase 1 | 12 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00529503] | Phase 2 | 151 participants (Actual) | Interventional | 2007-09-30 | Terminated | ||
| Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence[NCT02681302] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-06-07 | Active, not recruiting | ||
| Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995] | Phase 3 | 481 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial[NCT05786989] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-02-28 | Recruiting | ||
| An Open-Label, Pilot Study To Investigate Feasibility and Safety Of Using Bortezomib, Rituximab, Ifosfamide, Carboplatin, Etoposide As Salvage Regime In Previously Treated Patients With Diffuse Large B-Cell Lymphoma[NCT01226849] | Phase 1 | 6 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| Cytoreduction and Stem Cell Mobilization With Rituximab and ICE for Patients With Refractory or Relapsed CD20+ B-Cell IGL Eligible for ASCT: The RICE Protocol[NCT00005631] | Phase 2 | 0 participants | Interventional | 1999-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for ifosfamide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
[Treatment strategy of gray zone lymphomas].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2014 |
[Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2015 |
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
[Management of diffuse large B-cell lymphoma in the rituximab era].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
[Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2010 |
HIV-related lymphoma treated with maintenance thalidomide.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2005 |
[ALK-negative primary gastric anaplastic large cell lymphoma].
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cispl | 2007 |
34 trials available for ifosfamide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2023 |
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.
Topics: Adolescent; Carboplatin; Child; Etoposide; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Ritu | 2023 |
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; L | 2023 |
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2020 |
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R | 2020 |
Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbi | 2020 |
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female | 2018 |
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carbopl | 2019 |
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placeb
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
[Clinical Efficacy Comparison of Different Second Line Salvage Chemotherapy Regimens for the Treatment of Elderly Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Disea | 2016 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2017 |
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabin | 2008 |
[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2009 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cyta | 2010 |
Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2011 |
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic | 2003 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Pr | 2004 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2006 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
[CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyc | 1994 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1995 |
Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1996 |
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Com | 1997 |
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 1997 |
[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hem
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Data Interpretation, S | 1998 |
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Ho | 2001 |
44 other studies available for ifosfamide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2022 |
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposid | 2022 |
PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma | 2023 |
Bilateral sciatic nerve neurolymphomatosis: PET/CT findings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Craniospinal Irradiation; Cyclophospham | 2017 |
Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Etoposide; Female; Humans; Ifosfamid | 2019 |
Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct Syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disorder of Sex Development, 46,XY | 2019 |
Diffuse large B cell lymphoma with chromosomal translocation t(14;19)(q32;q13) occurring in IgG4-related disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chromosomes, Human, Pair 14; Chro | 2019 |
Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central | 2013 |
In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Cyclophosphamide; Flow Cytometry; | 2013 |
Anaplastic lymphoma kinase-positive large B-cell lymphoma: description of a case with an unexpected clinical outcome.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytara | 2015 |
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Topics: Acute Kidney Injury; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antibo | 2014 |
[Malignant lymphoma complicated with posterior reversible encephalopathy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Ifosfamide; | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; C | 2016 |
Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2016 |
Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Ne | 2010 |
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2011 |
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemoth | 2011 |
Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Ly | 2013 |
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Centra | 2013 |
[Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; | 2003 |
Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chromosomes, Human; Chromosomes, Human, | 2004 |
Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Etop | 2004 |
Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital.
Topics: Acetaminophen; Acid-Base Equilibrium; Acidosis; Adult; Analgesics, Non-Narcotic; Antineoplastic Comb | 2005 |
Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2005 |
Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Cyclophosphamide; Disease-Free Survival; Eye Neoplasms; Hum | 2005 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2006 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplati | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytarabine; Dex | 2007 |
Cutaneous plasmablastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposid | 2008 |
Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclo | 1983 |
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin | 1995 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
[Syndrome of inappropriate secretion of antidiuretic hormone and neurotoxicity induced by vincristine and alkylating agents during chemotherapy for malignant lymphoma of thyroid gland].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; C | 1998 |
p53 gene mutation in the bone-marrow of a patient with diffuse mixed cell type lymphoma at diagnosis predicting eventual progression to large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; Disease Progr | 1998 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1998 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combi | 2001 |
Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2001 |
Ifosfamide extrapyramidal neurotoxicity.
Topics: Adenocarcinoma; Basal Ganglia Diseases; Humans; Ifosfamide; Lung Neoplasms; Lymphoma, Large B-Cell, | 1991 |